Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Experiences of discrimination, a notable psychosocial stressor, are considered an important risk factor for problematic opioid use. We examined whether pain severity, pain interference, anxiety, and depressive symptoms are pathways through which discrimination may be associated with increased prescription opioid misuse behaviors among individuals with chronic pain.
Method: A total of 234 participants who reported being prescribed opioids for chronic pain management were included from a parent longitudinal study collected from Amazon's MTurk. Study variables were collected at baseline and 12-month follow-up. Path analyses tested the hypothesized model, with socio-demographic variables and outcomes measured at baseline included as covariates. Mediated effects were examined using percentile bootstrap method.
Results: After controlling for socio-demographic covariates, pain severity, pain interference, anxiety, and depressive symptoms, baseline discrimination was significantly associated with greater prescription opioid misuse behaviors (=.020) at 12 months. Baseline discrimination was also significantly associated with anxiety (<.001) and depressive symptoms (<.001) at 12 months. However, pain severity, pain interference, anxiety, and depressive symptoms were not significantly associated with prescription opioid misuse at 12 months. Mediation analyses indicated no significant effects.
Conclusions: Discrimination may play an important role in prescription opioid misuse behaviors among individuals with chronic pain. Furthermore, discrimination is a risk factor contributing to elevated anxiety and depressive symptoms, with broad clinical implications for individuals coping with chronic pain. However, pain severity, pain interference, anxiety and depressive symptoms did not emerge as underlying mechanisms that link discrimination and prescription opioid misuse. Replication and extension in future studies are warranted.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396542 | PMC |
| http://dx.doi.org/10.1037/sah0000573 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Clinical Pharmacy Team Intervention on Naloxone Fills in Patients on Chronic Opioid Therapy.
Perm J
September 2025
Department of Pharmacy, Kaiser Permanente Georgia, Atlanta, GA, USA.
Background: Opioids are highly effective for pain management but carry risks. Naloxone quickly reverses opioid overdoses by blocking opioid receptors in the brain. Despite its effectiveness, naloxone remains underutilized.
View Article and Find Full Text PDFWomen veterans and risk of illicit substance use and use disorders, 2015-2019 and 2021: A secondary analysis of the National Survey on Drug Use and Health.
Arch Psychiatr Nurs
October 2025
University of Pittsburgh School of Nursing, Department of Health and Community Systems, 3500 Victoria St. Pittsburgh, PA 15213, United States of America. Electronic address:
Background: Women veterans are at risk for substance use and substance use disorders, although there remains limited data on substance use in women veterans.
Methods: A secondary analysis of data from the National Survey on Drug Use and Health from 2015 to 2019 and 2021 was conducted to compare women veterans with women non-veterans and men veterans on substance-related outcomes, including lifetime substance use, frequency of past 30-day substance use, and past-year substance use disorders for cannabis, opioids, and stimulants.
Results: From 2015 to 2019, women veterans were about 53 % and 24 % more likely to have used cannabis in their lifetime compared to women non-veterans and men veterans, respectively.
Risks for adverse events by sex and age after prescription opioid dose reduction.
Am J Prev Med
September 2025
Kaiser Permanente Northern California, Division of Research, Center for Addiction and Mental Health Research, Pleasanton, CA, United States.
Introduction: Prescription opioid dose reductions can raise the risk of adverse events for patients on long-term opioid therapy for non-cancer pain. Evidence on whether risks differ by age or sex is needed to support tailored clinical decision-making.
Methods: In 2024, a secondary analysis of an observational cohort study was conducted across 8 U.
Comparative Effectiveness of Opioids and Opioid Substitutes on Pain and Health Related Quality of Life Among Cancer Survivors.
Cancer Med
September 2025
Department of Biostatistics & Data Science, School of Public and Population Health, University of Texas Medical Branch, Galveston, Texas, USA.
Introduction: Chronic pain is a major but modifiable contributor to poor quality of life among long-term cancer survivors. With growing concern over opioid-related risks, gabapentinoids have emerged as a safer alternative, though evidence comparing their effectiveness remains limited.
Methods: We conducted a retrospective cohort study using SEER-MHOS linked data (1998-2021) to examine pain interference and health-related quality of life (HRQoL) among 24,651 cancer survivors.
Constructing Opioid Legitimacy: The Canadian Pain Task Force's Framing of the Overdose Crisis.
J Law Med Ethics
September 2025
Dalla Lana School of Public Health, https://ror.org/03dbr7087University of Toronto, Canada.
The opioid overdose crisis has become a global public health emergency, claiming more than 100,000 lives each year. In North America, shifting opioid prescribing practices in response to the crisis have profoundly affected people living with chronic pain, who now face reduced access to prescription opioids. Against this backdrop, pain stakeholders have become increasingly active in policymaking arenas to shape how opioids and pain are understood.
View Article and Find Full Text PDF